<DOC>
	<DOCNO>NCT01744691</DOCNO>
	<brief_summary>An Open-label , Single arm , Multicenter Phase 2 Study Bruton 's Tyrosine Kinase Inhibitor ibrutinib Patients Relapsed Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma 17p Deletion</brief_summary>
	<brief_title>A Multicenter Phase 2 Study Ibrutinib Patients With Relapsed Refractory Chronic Lymphocytic Leukemia ( CLL ) Small Lymphocytic Lymphoma ( SLL ) With 17p Deletion</brief_title>
	<detailed_description>This multicenter , international , open-label , single arm , Phase 2 study design evaluate efficacy safety ibrutinib subject relapsed/refractory CLL SLL del 17p . All subject receive ibrutinib disease progression unacceptable toxicity occur .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Key Documentation del ( 17p13.1 ) Must relapse refractory CLL/SLL receive least 1 prior line systemic therapy . Measurable nodal disease compute tomography ( CT ) Key History current evidence Richter 's transformation prolymphocytic leukemia Prior hematologic stem cell transplantation &lt; 6 month study enrollment ongoing GVHD Prior exposure ibrutinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
</DOC>